Experimental autoimmune encephalomyelitis

• Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential (27 Aug 2024)
  
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders (25 Aug 2024)
  
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders (21 Aug 2024)
  
• Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination (21 Aug 2024)
  
• The Treatment of Cognitive, Behavioural and Motor Impairments from Brain Injury and Neurodegenerative Diseases through Cannabinoid System Modulation—Evidence from In Vivo Studies (20 Aug 2024)
  
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases (20 Aug 2024)
  
• Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges (18 Aug 2024)
  
• Medicinal Cannabis and Central Nervous System Disorders (31 Jul 2022)
  
• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty (31 Jul 2022)